Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT05371496
StatusCompleted
PhasePhase 4
SponsorMayo Clinic
Enrollment81 participants
DesignInterventional, Randomized, Parallel, Masking: Double
ConditionsCardiomyopathy; Heart Failure With Preserved Ejection Fraction (HFpEF); Obesity
InterventionsSemaglutide; Placebo; Counselling on healthy lifestyle intervention
StartSep 6, 2022
Primary completionJul 17, 2026
Study completionJul 17, 2026
Results postedNot yet
Registry last updatedAug 14, 2026
CollaboratorsUnited States Department of Defense

Compounds on this site that cite this trial

What the registry says the trial is about

The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Pulmonary Capillary Wedge Pressure (PCWP)Baseline, 12 months

28 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.

Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.

Share thisFacebookXEmail